Sulindac and its metabolites: Sulindac sulfide and sulindac sulfone enhance cytotoxic effects of arsenic trioxide on leukemic cell lines

Toxicology in Vitro

Volumn 25, Issue 5, 2011, Pages 1075-1084

  Stepnik, Maciej ^a   Ferlińska, Magdalena ^a   Smok Pieniazek, Anna ^a   Gradecka Meesters, Dobrosława ^a   Arkusz, Joanna ^a   Stańczyk, Małgorzata ^a  

^a NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

Author keywords

Apoptosis; Arsenic trioxide; Leukemic cells; Sulindac; Sulindac sulfide; Sulindac sulfone

Indexed keywords

ARSENIC TRIOXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL MEMBRANE PERMEABILITY; CELL STRAIN HL 60; CELL STRAIN K 562; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DEPOLARIZATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOCYTE; MITOCHONDRIAL DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN;

ANIMALS; ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; DRUG SYNERGISM; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; JURKAT CELLS; K562 CELLS; LYMPHOCYTES; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; NF-KAPPA B; OXIDES; PROPIDIUM; STAINING AND LABELING; SULINDAC;

EID: 79957967638     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2011.04.011     Document Type: Article

References (60)

1. Amrán D., Sánchez Y., Fernández C., et al. Arsenic trioxide sensitizes promonocytic leukemia cells to TNFalpha-induced apoptosis via p38-MAPK-regulated activation of both receptor-mediated and mitochondrial pathways. Biochim. Biophys. Acta 2007, 1773:63-1653.
2. Au W.Y., Tam S., Fong B.M., Kwong Y.L. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood 2008, 112:3587-3590.
3. Bahlis N.J., McCafferty-Grad J., Jordan-McMurry I., et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res. 2002, 8:3658-3668.
4. Berman K.S., Verma U.N., Harburg G., et al. Sulindac enhances tumor necrosis factor-alpha-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-kappaB. Clin. Cancer Res. 2002, 8:354-360.
5. Chen D., Chan R., Waxman S., Jing Y. Buthionine sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2-terminal kinase and up-regulation of death receptors. Cancer Res. 2006, 66:23-11416.
6. Czibere A., Prall W.C., Zerbini L.F., et al. Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS. Br. J. Haematol. 2006, 135:7-355.
7. Dai C.W., Zhang G.S., Shen J.K., et al. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients. Acta Haematol. 2009, 121:1-8.
8. Dilda P.J., Hogg P.J. Arsenical-based cancer drugs. Cancer Treat. Rev. 2007, 33:64-542.
9. Giardiello F.M., Yang V.W., Hylind L.M., et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N. Eng. J. Med. 2002, 346:9-1054.
10. Giovannucci E., Rimm E.B., Stampfer M.J., et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Int. Med. 1994, 121:6-241.
11. Goldberg Y., Nassif I.I., Pittas A., et al. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 1996, 12:893-901.
12. Grad J.M., Bahlis N.J., Reis I., et al. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001, 98:805-813.
13. Han E.K., Arber N., Yamamoto H., et al. Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines. Breast Cancer Res. Treat. 1998, 48:195-203.
14. Han S.S., Kim K., Hahm E.R., et al. Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. J. Cell Biochem. 2005, 94:695-707.
15. Han Z., Pantazis P., Wyche J.H., et al. A Fas-associated death domain protein-dependent mechanism mediates the apoptotic action of non-steroidal anti-inflammatory drugs in the human leukemic Jurkat cell line. J. Biol. Chem. 2001, 276:38748-38754.
16. Hanif R., Pittas A., Feng Y., et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 1996, 52:237-245.
17. He T.C., Chan T.A., Vogelstein B., Kinzler K.W. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999, 99:335-345.
18. Herrmann C., Block C., Geisen C., et al. Sulindac sulfide inhibits Ras signaling. Oncogene 1998, 17:1769-1776.
19. Jiang T.T., Brown S.L., Kim J.H. Combined effect of arsenic trioxide and sulindac sulfide in A549 human lung cancer cells in vitro. J. Exp. Clin. Cancer Res. 2004, 23:62-259.
20. Jin H.O., Yoon S.I., Seo S.K., et al. Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin. Biochem. Pharmacol. 2006, 72:36-1228.
21. Jin H.O., Seo S.K., Woo S.H., et al. A combination of sulindac and arsenic trioxide synergistically induces apoptosis in human lung cancer H1299 cells via c-Jun NH2-terminal kinase-dependent Bcl-xL phosphorylation. Lung cancer 2008, 61:27-317.
22. Kim B.Y., Gaynor R.B., Song K., et al. Constitutive activation of NF-kappaB in Ki-ras-transformed prostate epithelial cells. Oncogene 2002, 21:4490-4497.
23. Kim H.R., Kim E.J., Yang S.H., et al. Combination treatment with arsenic trioxide and sulindac augments their apoptotic potential in lung cancer cells through activation of caspase cascade and mitochondrial dysfunction. Int. J. Oncol. 2006, 28:8-1401.
24. Kumana C.R., Au W.Y., Lee N.S., et al. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur. J. Clin. Pharmacol. 2002, 58:6-521.
25. Lee H.R., Cheong H.J., Kim S.J., et al. Sulindac enhances arsenic trioxide-mediated apoptosis by inhibition of NF-kappaB in HCT116 colon cancer cells. Oncol. Rep. 2008, 20:7-41.
26. Lim J.T.E., Piazza G.A., Pamukcu R., et al. Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells. Clin. Cancer Res. 2003, 9:4972-4982.
27. Litzow M.R. Arsenic trioxide. Expert Opin. Pharmacother. 2008, 9:1773-1785.
28. Loveridge C.J., MacDonald A.D., Thoms H.C., et al. The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappaB. Oncogene 2008, 17:2648-2655.
29. Mathas S., Lietz A., Janz M., et al. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 2003, 102:34-1028.
30. Mathieu J., Besançon F. Clinically tolerable concentrations of arsenic trioxide induce p53-independent cell death and repress NF-kappa B activation in Ewing sarcoma cells. Int. J. Cancer 2006, 119:7-1723.
31. Nikitakis N.G., Hamburger A.W., Sauk J.J. The nonsteroidal anti-inflammatory drug sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells. Cancer Res. 2002, 62:1004-1007.
32. Oshima M., Dinchuk J.E., Kargman S.L., et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87:9-803.
33. Park J.H., Kim E.J., Jang H.Y., et al. Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. Oncol. Rep. 2008, 20:84-379.
34. Piazza G.A., Alberts D.S., Hixson L.J., et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 1997, 57:2909-2915.
35. Piazza G.A., Rahm A.K., Finn T.S., et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 1997, 57:2452-2459.
36. Platanias L.C. Biological responses to arsenic compounds. J. Biol. Chem. 2009, 284:18583-18587.
37. Qazilbash M.H., Saliba R.M., Nieto Y., et al. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol. Blood Marrow Transpl. 2008, 14:1401-1407.
38. Qiu W., Wang X., Leibowitz B., et al. Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis. Proc. Natl. Acad. Sci. USA 2010, 107:32-20027.
39. Ravis W.R., Diskin C.J., Campagna K.D., et al. Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure. J. Clin. Pharmacol. 1993, 33:527-534.
40. Reeder M.K., Pamakcu R., Weinstein I.B., et al. Select cyclic nucleotide phosphodiesterase inhibitors in colon tumor chemoprevention. Cancer Chemoprevention: Promising Cancer Chemopreventive Agents 2004, 18-401. Humana Press. J. Gary, E.T. Kelloff, C. Hawk, C. Sigman (Eds.).
41. Roboz G.J., Ritchie E.K., Curcio T., et al. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer 2008, 113:2504-2511.
42. Shen Z.X., Chen G.Q., Ni J.H., et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89:3354-3360.
43. Soriano A.F., Helfrich B., Chan D.C., et al. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res. 1999, 59:6178-6184.
44. Taketo M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J. Natl. Cancer Inst. 1998, 90:1609-1620.
45. Thompson H.J., Briggs S., Paranka N.S., et al. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. J. Nat. Cancer Inst. 1995, 87:1259-1260.
46. Thompson W.J., Piazza G.A., Li H., et al. Exisulind induction of apoptosis involves guanosine 3', 5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000, 60:3338-3342.
47. Tinsley H.N., Gary B.D., Keeton A.B., et al. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol. Cancer Ther. 2009, 8:40-3331.
48. Tinsley H.N., Gary B.D., Thaiparambil J., et al. Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev. Res. (Phila.) 2010, 3:13-1303.
49. Vane J.R., Bakhle Y.S., Botting R.M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 1998, 38:97-120.
50. Van Stolk R., Stoner G., Hayton W.L., et al. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin. Cancer Res. 2000, 78:78-89.
51. Wang X., Kingsley P.J., Marnett L.J., Eling T.E. The role of NAG-1/GDF15 in the inhibition of intestinal polyps in APC/Min mice by sulindac. Cancer Prev. Res. (Phila.) 2011, 4:60-150.
52. Whitehead C.M., Earle K.A., Fetter J., et al. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol. Cancer Ther. 2003, 2:479-488.
53. Wilson A.J., Velcich A., Arango D., et al. Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. Cancer Res. 2002, 62:6006-6010.
54. Yamamoto Y., Yin M.J., Lin K.M., Gaynor R. Sulindac inhibits activation of NF-κB pathway. J. Biol. Chem. 1999, 274:27307-27314.
55. Yamamoto M., Hirano S., Vogel C.F., et al. Selective activation of NF-kappaB and E2F by low concentration of arsenite in U937 human monocytic leukemia cells. J. Biochem. Mol. Toxicol. 2008, 22:46-136.
56. Zanotto-Filho A., Braganhol E., Schröder R., et al. NFκB inhibitors induce cell death in glioblastomas. Biochem. Pharmacol. 2011, 81:24-412.
57. Zhang L., Yu J., Park B.H., et al. Role of BAX in the apoptotic response to anticancer agents. Science 2000, 290:989-992.
58. Zhang T., Westervelt P., Hess J.L. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3). Mod. Pathol. 2000, 13:61-954.
59. Zhang X., Morham S.G., Langenbach R., Young D.A. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J. Exp. Med. 1999, 190:9-451.
60. Zhou H., Liu W., Su Y., et al. NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling. Cancer Cell 2010, 17:73-560.